Species Mediators Findings References Tumor promoting role Human VEGF IL-17 induces both CRC cell lines and primary cancer cells to produce VEGF. [ 52] Human HIF-1
IL-17 and TNF
cooperatively stimulate glycolysis in CRC cells via induction of HIF-1
and c-myc expression.
[ 45] Mouse Stat 3 IL-23/IL-17 signaling activated by microbial products promotes STAT3 phosphorylation in CRC epithelial cells. [ 48] Mouse VEGF, KC, and PGE2 IL-17 promotes angiogenesis via induction of a variety of proangiogenic factors secretion from fibroblasts and tumors. [ 36] Mouse IL-6, IL-23, and IL-1
KC and Cox-2; CD4 T cells IL-6, IL-23, IL-1
, KC, and Cox-2 are decreased and function of CD4 T cells alters in Apc
Min/+ mice, resulting in abrogating spontaneous intestinal tumorigenesis. [ 17] Mouse IL-6, STAT3, and TNF-
cyclin D1, cyclin-dependent kinase 2, and cyclin E IL-17A knockout decreases IL-6, STAT3, TNF-
, cyclin-D1, cyclin-dependent kinase 2, and cyclin E and inhibits CAC tumorigenesis.
[ 46] Mouse G-CSF, VEGF, and Bv8 NF-
B and ERK signaling
IL-17 induces the expression of G-CSF through NF-
B and ERK signaling, enhancing proangiogenic function via VEGF and Bv98 and promoting tumor growth.
[ 50] Tumor inhibiting activity Mouse IFN-
NK cells and T cells IL-17-deficient decreases IFN-
NK and tumor-specific IFN-
T cells and promotes tumor growth and lung metastasis.
[ 53] Human Claudin ERK MAPK pathway IL-17 enhances the development of the tight junctional barrier mediated by claudin of T84-cell monolayers via ERK MAPK pathway in intestine. [ 54]